Acurx Pharmaceuticals, Inc. Common Stock
ACXP
ACXP: Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
moreShow ACXP Financials
Recent trades of ACXP by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ACXP's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Dna polymerase iiic inhibitors and use thereof May. 11, 2021
-
Patent Title: Dna polymerase iiic inhibitors and use thereof Nov. 17, 2020
-
Patent Title: Dna polymerase iiic inhibitors and use thereof Jul. 28, 2020
Federal grants, loans, and purchases
Followers on ACXP's company Twitter account
Number of mentions of ACXP in WallStreetBets Daily Discussion
Recent insights relating to ACXP
Recent picks made for ACXP stock on CNBC
ETFs with the largest estimated holdings in ACXP
Flights by private jets registered to ACXP